Quest distributes Abbott bladder cancer probe:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics has agreed to distribute Abbott Laboratories' bladder cancer probe, Vysis UroVision DNA probe assay, in the US. New labelling claims on the product's effectiveness in monitoring bladder cancer recurrence were cleared by the FDA in March 2002. Vysis UroVision is based on fluorescence in situ hybridisation (FISH) technology, with which cancer cells can be examined while physically intact and are this not destroyed. Quest has been distributing Abbott's FISH-based breast cancer-diagnostic, PathyVision Her-2, since December 2001.